SOAT1 and systemic lupus erythematosus: In a phase two trial of baricitinib (a JAK1- and JAK2-selective inhibitor), gene expression profiling revealed the suppression of interferon-responsive genes following 24 weeks of study treatment, in addition to the suppression of JAK-STAT signaling and other genes involved in SLE immunopathogenesis [119].